Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SRC | P12931 | 8/20 | 0.50 |
| ▸ | EGFR | P00533 | 8/20 | 0.50 |
| ▸ | KDR | P35968 | 9/20 | 0.49 |
| ▸ | CSK | P41240 | 3/20 | 0.49 |
| ▸ | TEK | Q02763 | 3/20 | 0.49 |
| ▸ | EPHB4 | P54760 | 1/20 | 0.49 |
| ▸ | RET | P07949 | 2/20 | 0.47 |
| ▸ | KIF5B | P33176 | 1/20 | 0.47 |
| ▸ | ERBB2 | P04626 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4027347 | 0.98 | EGFR (0.52) | SRCEGFRKDRCSKTEK | |
| SCHEMBL4026371 | 0.95 | SRC (0.54) | SRCEGFRKDRCSKTEK | |
| SCHEMBL4026562 | 0.92 | EGFR (0.53) | SRCEGFRKDRCSKTEK | |
| SCHEMBL4020660 | 0.91 | EGFR (0.53) | SRCEGFRKDRCSKTEK | |
| SCHEMBL4027299 | 0.89 | SRC (0.56) | SRCEGFRKDRCSKTEK | |
| SCHEMBL4025139 | 0.86 | SRC (0.55) | SRCEGFRKDRCSKTEK | |
| SCHEMBL4021449 | 0.86 | SRC (0.54) | SRCEGFRKDRCSKTEK | |
| SCHEMBL4025403 | 0.85 | SRC (0.62) | SRCEGFRKDRCSKTEK | |
| SCHEMBL4030245 | 0.85 | SRC (0.54) | SRCEGFRKDRCSKTEK | |
| SCHEMBL4024530 | 0.84 | SRC (0.61) | SRCEGFRKDRCSKTEK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1528925-A1 | QUINAZOLINE DERIVATIVES FOR USE IN THE TREATMENT OF CANCER | Astrazeneca AB (SE) | 2005-05-11 | — | — | EP | disclosed |
| WO-2004004732-A1 | QUINAZOLINE DERIVATIVES FOR USE IN THE TREATMENT OF CANCER | ASTRAZENECA AB (SE) | 2004-01-15 | — | — | WO | disclosed |